ID: MRFR/Pharma/3249-HCR | 115 Pages | Published By Rahul Gotadki on March 2023
Figure: Global Acquired Aplastic Anemia Market, By Region Market Share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
Acquired Aplastic Anemia Market Segmentations
The global acquired aplastic anemia market is segmented on the basis of types, by diagnosis, by treatment, and by end user.
On the basis of type, it is segmented into moderate aplastic anemia, severe aplastic anemia, and very severe aplastic anemia.
On the basis of diagnosis, it is segmented into bone marrow biopsy, X-rays, computed tomography (CT) scans, and others.
On the basis of treatment, it is segmented into bone marrow transplantation, immunosuppressive therapies, and others.
On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.
Acquired Aplastic Anemia Market Regional Analysis
The Americas dominate the global acquired aplastic anemia market owing to well-developed technology, increasing patient with blood disorders, increasing prevalence of cancer, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the global acquired aplastic anemia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.
Asia Pacific is the fastest growing acquired aplastic anemia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the acquired aplastic anemia in the region.
On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.
Acquired Aplastic Anemia Market Key Players
Some of key the players in the acquired aplastic anemia market are
Sources: Annual reports, Press release, White paper, and Company presentation
|Market Size||2030: USD 10,246.1 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Diagnosis, Treatment, And End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), CSL Limited (Australia), Amgen Inc., GlaxoSmithKline plc., and Bluebird bio.|
|Key Market Opportunities||
|Key Market Drivers||